This study is currently not recruiting participants.

A Long-Term Open-Label Follow-Up Study of CP-690 550 for Treatment of Juvenile Idiopathic Arthritis (JIA)

Investigating Long-Term Safety and Tolerability for Juvenile Idiopathic Arthritis (a type of arthritis in children) Treatment

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to determine the long term safety and tolerability of CP-690,550 for treatment of the signs and symptoms of JIA (Juvenile Idiopathic Arthritis).

Detailed description of study

The purpose of this study is to determine the long term safety and tolerability of CP-690,550 for treatment of the signs and symptoms of JIA (Juvenile Idiopathic Arthritis).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Juvenile Idiopathic Arthritis
  • Age: 100 years or below
  • Gender: All

This study investigates the long-term safety and tolerability of an investigational medication for treating the signs and symptoms of Juvenile Idiopathic Arthritis (JIA). JIA is a condition in children that causes joint pain and swelling.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.

  • Who can participate: Children diagnosed with Juvenile Idiopathic Arthritis, typically aged 2 to 16 years, who meet specific health criteria.
  • Study details: Participants will receive the investigational medication.
Updated on 19 Feb 2024. Study ID: 1501338992

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team